

# VBC Release Highlights

November 1, 2024

Practice Insights<sup>SM</sup> is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS) and Enhancing Oncology Model (EOM).

## EOM Quality Measures Dashboard

Starting Monday, Nov. 4, 2024, the following columns will now display data as expected:

- Pain Present at Encounter
- Age at Encounter
- Referral to Provider

---

## MIPS Quality Measures Dashboard

Starting Monday, Nov. 4, 2024, MIPS #128: Body Mass Index (BMI) Screenings and Follow-Up Plan will be removed from the dashboard. Data will continue to be available within the dashboard for 2023 and all prior years this measure was supported.

---

## Status of Dashboard Updates for 2024

CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2024 requirements. The measures listed below either have no 2024 update required or have been updated.

Measure	Description
<b>MIPS Quality Measures Dashboard</b>	
#001	Diabetes Hemoglobin A1c (HbA1c) Poor Control (>9%) (Inverse Measure)
#047	Advance Care Plan
#104	Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer
#128	BMI (This measure is no longer a MIPS Traditional Measure)
#130	Current Medications
#134 eCQM	Preventive Care Screening: Screening for Depression and Follow-Up Plan
#134 CQM / Registry	Preventive Care Screening: Screening for Depression and Follow-Up Plan
#143	Pain Intensity Quantified
#144	Pain Care Plan
#226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
#236	Controlling High Blood Pressure
#238	Use of High-Risk Medications in Older Adults
#374	Closing the Referral Loop
#450	Trastuzumab Received by Patients with AJCC Stage I (T1c), II and III and HER2+ Breast Cancer Receiving Adjuvant Chemotherapy
#451	RAS (KRAS & NRAS) Testing Performed for Patients

Measure	Description
	with Metastatic Colorectal Cancer who Received Anti-EGFT Monoclonal Antibody Therapy
#452	Percentage of Adult Patients (aged 18 or older) with Metastatic Colorectal Cancer and RAS (KRAS & NRAS) Gene Mutation Spared Treatment with Anti-EGFR Monoclonal Antibodies
#453	Percentage of Patients Who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 14 Days of Life (Inverse Measure)
#457	Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (Inverse Measure)
#462	Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy
#487	Screenings for Social Drivers of Health
PIMSH #1	Advance Care Planning in Stage 4 Disease
PIMSH #2	Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)
PIMSH #4	Patient-Reported Pain Improvement
PIMSH #9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH #10	Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs
PIMSH #13	Proportion of Stage IV nsNSCLC Patients Tested for Actionable Biomarkers and Received Mutation-Targeted Therapy (EGFR, BRAF, ROS1, ALK, PD-L1)

Measure	Description
PIMSH #15	Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
PIMSH #16	Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center